GlaxoSmithKline plc (GSK) Shares Bought by First Trust Advisors LP
First Trust Advisors LP lifted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 26.1% during the fourth quarter, HoldingsChannel reports. The firm owned 619,519 shares of the pharmaceutical company’s stock after acquiring an additional 128,188 shares during the quarter. First Trust Advisors LP’s holdings in GlaxoSmithKline were worth $21,974,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. Field & Main Bank acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth about $132,000. First Dallas Securities Inc. acquired a new position in GlaxoSmithKline in the 4th quarter valued at about $142,000. Wealthcare Advisory Partners LLC increased its position in GlaxoSmithKline by 1,982.8% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the period. Waldron LP acquired a new position in GlaxoSmithKline in the 3rd quarter valued at about $203,000. Finally, Belpointe Asset Management LLC acquired a new position in GlaxoSmithKline in the 3rd quarter valued at about $204,000. Institutional investors and hedge funds own 9.17% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. TheStreet cut GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Kepler Capital Markets upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 5th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $38.97.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The company had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. equities research analysts forecast that GlaxoSmithKline plc will post 2.93 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a yield of 6.87%. The ex-dividend date is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s payout ratio is currently 320.26%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-shares-bought-by-first-trust-advisors-lp/1889383.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.